The more you understand about primary immunodeficiency (PI), the better you can live with the disease or support others in your life with PI. Learn more about PI, including the various diagnoses and treatment options.
Living with primary immunodeficiency (PI) can be challenging, but you’re not alone—many people with PI lead full and active lives. With the right support and resources, you can, too.
Be a hero for those with PI. Change lives by promoting primary immunodeficiency (PI) awareness and taking action in your community through advocacy, donating, volunteering, or fundraising.
Whether you’re a clinician, researcher, or an individual with primary immunodeficiency (PI), IDF has resources to help you advance the field. Get details on surveys, grants, and clinical trials.
Many children and teens living with severe combined immunodeficiency (SCID) today weren’t identified with SCID through newborn screening. Instead, as infants, they suffered life-threatening infections for several months or more before doctors determined they had SCID, a primary immunodeficiency that is fatal unless a baby receives a transplanted immune system.
Often these babies with SCID remained in the hospital in critical condition, as they struggled with prolonged malnutrition and severe infections like meningitis and pneumonia.
Due to both the lengthy hospital stays and the infections, some of these patients may have experienced neurodevelopmental problems, such as cognitive delays and slower development of motor and verbal skills, that ultimately affected school performance.
A new study is underway to compare how those not diagnosed with SCID through newborn screening are progressing neurologically compared to those diagnosed with SCID through newborn screening.
Newborn screening for SCID was gradually introduced into state newborn screening panels between the years of 2008 and 2018, and all states currently screen for SCID as part of the heel stick blood screening performed within 24 to 48 hours after birth.
Newborn screening for SCID leads to early diagnosis and often treatment within the first few months of life. Treatment with either a bone marrow transplant or gene therapy provides the baby with a functioning immune system before damaging and life-threatening infections set in.
The hypothesis of the study is that adverse neurodevelopmental outcomes are reduced with newborn screening. Researchers will compare neurodevelopmental outcomes of those diagnosed with SCID through newborn screening versus those diagnosed through clinical manifestations such as infections to test the hypothesis.
Another factor researchers intend to examine when evaluating neurodevelopmental progress is the chemotherapy persons with SCID received as part of their treatments. Chemotherapy is necessary to prepare the person for a new immune system and to ensure a successful transplant. However, it can negatively affect cognitive abilities. It’s critical to determine whether chemotherapy improves or worsens cognitive outcomes.
IDF’s SCID Compass program is partnering with the Primary Immune Deficiency Treatment Consortium to perform the collaborative study, which began in 2020 and is funded by the Health Resources and Services Administration of the U.S. Department of Health and Human Services.
Receive news and helpful resources to your cell phone or inbox. You can change or cancel your subscription at any time.
The Immune Deficiency Foundation improves the diagnosis, treatment, and quality of life for every person affected by primary immunodeficiency.
We foster a community that is connected, engaged, and empowered through advocacy, education, and research.
Combined Charity Campaign | CFC# 66309